News
MinervaX announces results from Phase I clinical trial
MinervaX announces positive results from Phase I trial in 240 healthy adult women with its innovative Group B Streptococcal (GBS) vaccine to prevent life-threatening infections...
Innovation Foundation Grant
MinervaX announces that the company has been awarded a grant worth DKK 4.1 million (EUR 0.6 million) from the Danish Innovation Foundation, under the Innobooster Programme, for...
Primary Endpoint Data from Phase I Part B
MinervaX announces that it today data have been received from the primary 3-month time point clinical endpoint of the Phase I Part B. The data supports dose-selection made based...
Completion of enrollment of Phase I Part B
MinervaX announces that it today has enrolled and dosed the last of 240 subjects in it Phase I Part B Dose-confirmation trial on its Group B Streptococcal vaccine GBS-NN.
Equity Financing
MinervaX announces that the company has raised DKK 16 million (EUR 2.2 million) for the development of its Group B Streptococcal Vaccine. The financing was a combination of an...
Innovation Foundation Grant
MinervaX announces that the company has been awarded a grant worth DKK 4.5 million (EUR 0.6 million) from the Danish Innovation Foundation, under the Innobooster Programme, for...
Initiation of Phase I Part B
MinervaX announces that it today has dosed the first subject in it Phase I Part B Dose-confirmation trial on its Group B Streptococcal vaccine GBS-NN, due to enrol 240 healthy...
Participation in Bill & Melinda Gates Foundation Grant
MinervaX announces that the company is a participant in a BMGF grant worth USD 0.5 million. Awarded to Professor Sharbir Madhi, South Africa for studies on correlates of...
Initiation of Phase I clinical trial
MinervaX initiates phase I clinical trial with innovative Group B Streptococcal (GBS) vaccine to prevent life-threatening infections in newborns. Novel, single component vaccine...